A first-of-its-kind antiviral gel may offer the potential to stop papillomavirus (HPV) infection before it causes cancer. ( ...

Eli Lilly LLY announced that it is increasing its manufacturing capacity in the United States by building four new plants.

LLY is increasing its manufacturing capacity in the United States by building four new plants. AZN's phase III study on camizestrant meets primary endpoint.

The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatme ...

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment Camizestrant improved patient survival without the disease getting ...

AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of ...

Astrazeneca plc’s good news with its oral selective estrogen receptor degrader (SERD) and estrogen receptor antagonist, ...

AstraZeneca's experimental breast cancer drug camizestrant, when combined with a cyclin-dependent kinase inhibitor, has shown significant improvement in delaying disease progression in patients with ...

Find insight on AstraZeneca, Fresenius, ConvaTec, and more in the latest Market Talks covering the Health Care sector.

Interim data has shown benefits of the camizestrant combo over standard treatment in ESR1-mutant breast cancer.

Astrazeneca shares rose nearly 1% following unexpectedly positive interim results from a Phase III trial of its breast cancer drug Camizestrant. The study revealed that patients with hormone ...